Issue link: http://osercommunicationsgroup.uberflip.com/i/668575
C h a i n D r u g s t o r e D a i l y 2 7 S a t u r d a y, A p r i l 1 6 , 2 0 1 6 IMMUNE DESIGN'S GLAAS PLATFORM SHOWN TO MODULATE ALLERGIC IMMUNE RESPONSE Immune Design, a clinical-stage immunotherapy company focused on oncology, has announced the presenta- tion of data demonstrating the potential of its GLAAS™ platform to modify allergic immune responses present in pollen and peanut allergies. Results from these studies were highlighted at the 2016 American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Los Angeles. Immune Design presented data high- lighting the ability of GLA, a synthetic TLR4 agonist and the core of the GLAAS platform, to modify the abnor- mal allergic immune response observed in peripheral blood from patients with pollen allergies. Specifically, the research demonstrated that GLA significantly decreased the level of Th2 cytokines, IL- 5 and IL-13, and increased the level of Th1 cytokines, IFNγ and IL-12, to grass pollen allergen in the peripheral blood mononuclear cells from allergic donors. Th2 cytokines promote the development of an allergic inflammatory response in people with allergies. Th1 cytokines can counterbalance Th2 immune responses and potentially aid in the treatment of allergic diseases. "These presentations add to the large and growing body of data supporting the potential of the GLAAS platform for the treatment of chronic diseases beyond cancer, where Immune Design is focused, including allergy," said Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design. "Investigational agents leveraging GLAAS in oncology are currently in clinical development in randomized Phase 2 studies in soft tissue sarcoma and Non-Hodgkin's lymphoma. Via selective external collaborations and licenses, we are expanding its development in other novel diseases such as peanut food aller- gy and infectious diseases such as respi- ratory syncytial virus." Immune Design's GLAAS platform works in vivo and is based on a small synthetic molecule called GLA, or glu- copyranosyl lipid adjuvant. GLA selec- tively binds to the TLR4 receptor and causes potent activation of dendritic cells (DCs) leading to the production of cytokines and chemokines that drive a Th1-type immune response. When GLA is accompanied by an antigen and injected into a patient, the combination is taken up by DCs and leads to the pro- duction and expansion of immune cells called CD4 T helper lymphocytes with a Th1 phenotype. These CD4 T cells play a key role in boosting pre-existing CTLs that are specific to the same anti- gen, neutralize a Th2 phenotype; and provide help to other immune cells and natural killer cells that are also impor- tant in the overall immune response. GLA can also be used to induce local and systemic immune responses against cancer by directly injecting it into tumors, where it induces a pro-inflam- matory state of the tumor microenviron- ment. Immune Design believes that GLAAS product candidates have the potential to target multiple types of can- cer, as well as infectious, allergic and autoimmune diseases. GLAAS-based product candidates have now been eval- uated in over 1400 subjects in Phase 1 and Phase 2 trials demonstrating an acceptable safety profile. About Immune Design Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight chronic diseases. The company's tech- nologies are engineered to activate the immune system's natural ability to gener- ate and/or expand antigen-specific cyto- toxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary focus of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex™ and GLAAS, the fundamental technolo- gies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com. ONCOTHYREON APPOINTS SCOTT D. MYERS CHIEF EXECUTIVE OFFICER Oncothyreon Inc., a clinical-stage bio- pharmaceutical company dedicated to the development of therapeutic products to improve the lives and outcomes of patients with cancer, has announced the appointment of Scott D. Myers as President, Chief Executive Officer and a member of the Board of Directors, effec- tive April 4, 2016. Myers, 49, brings more than 20 years of industry expertise, including significant management, commercial- ization and business development expe- rience in multinational pharmaceutical companies. Myers most recently served as Chief Executive Officer and President for Aerocrine AB, a life sci- ences company based in Stockholm, Sweden and Morrisville, North Carolina. Aerocrine was acquired by Circassia Pharmaceuticals, a U.K.-based immunotherapy company, in July of 2015. Myers also served as an independ- ent Director for Orexo, AB, a pharma- ceutical company and is currently an industry advisor to EQT, a large Scandinavian investment fund. Prior to joining Aerocrine in 2011, Myers served as Vice President, Head of European Mid-Markets for UCB, a Belgian-based, global biopharmaceutical company. In this role, Myers oversaw commercial operations and medical affairs for 32 countries in the EU. Prior to UCB, Myers served in senior roles responsible for business development, strategic marketing and pharmaceutical portfolio management at several leading companies including Johnson & Johnson. Myers received an MBA from the University of Chicago and a BA in Biology from Northwestern University. "Scott brings a wealth of operational, business development and commercial experience that we believe will be invalu- able to Oncothyreon," said Christopher S. Henney, Ph.D., D.Sc., Chairman of the Oncothyreon Board of Directors. "His significant leadership across multiple areas in the biopharmaceutical arena will serve the company well, both in terms of product development and leveraging business development opportunities to strengthen the company." "I believe Oncothyreon's product pipeline, led by ONT-380 for HER2-pos- PTS DIAGNOSTICS PRODUCTS NOW DISTRIBUTED BY ANDA PTS Diagnostics, the U.S.-based man- ufacturer of point-of-care biometric testing devices, including the CardioChek ® family of analyzers, A1CNow ® systems, and PTS Detect™ cotinine systems, has announced that it has signed a national sales and distri- bution agreement with Anda, an Allergan company. Anda is a national medical distribution company that sells over-the-counter pharmaceutical products to retail independent and chain pharmacies, nursing homes, mail-order pharmacies, hospitals, clin- ics and physician offices. Anda is the fourth largest supplier of generic phar- maceuticals in the U.S., and is a pre- mier distributor for new-to-market product launches to retail chains. For more information, visit www .ptsdiagnostics.com. itive breast cancer, offers promise to impact the future of cancer treatment," said Myers. "I look forward to leading the management team and working with the Board to guide the advancement of Oncothyreon's innovative therapeutic products as well as pursuing opportuni- ties to further strengthen the company and build stockholder value." In connection with Myers' appoint- ment, Oncothyreon's Compensation Committee granted him an inducement stock option to purchase 2,848,855 shares of common stock pursuant to the NASDAQ Listing Rule 5635(c)(4). The stock option grant will be effective on April 4, 2016, the date Myers' employ- ment commences. The exercise price of the inducement stock option will be the closing price of Oncothyreon's common stock on the effective date of the grant, and 25 percent of the award will vest on the first anniversary of the grant date, with the remaining portion of the option vesting monthly thereafter, subject to Myers' continued service. About Oncothyreon Oncothyreon is a clinical-stage biophar- maceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Its goal is to discover, develop and commer- cialize novel compounds that have the potential to improve the lives and out- comes of cancer patients. Its most advanced product candidate is ONT-380, an orally active and selective small mol- ecule HER2 inhibitor. For more information, visit www.oncothyreon.com.